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Abstract
Background:  As cyclin-dependent kinase 5 (CDK5) has been implicated in the abnormal
hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of
neurofibrillary tangles, we examined the contribution of this gene to the susceptibility for AD.
Methods:  We examined genetic variations of CDK5 by genotyping haplotype tagging SNPs
(htSNPs) (rs9278, rs2069459, rs891507, rs2069454, rs1549759 and rs2069442) in a group of 408
Spanish AD cases and 444 controls.
Results: There were no differences in the genotypic, allelic or haplotypic distributions between
cases and controls in the overall analysis or after stratification by APOE ε4 allele.
Conclusion: Our negative findings in the Spanish population argue against the hypothesis that
CDK5 genetic variations are causally related to AD risk. Still, additional studies using different sets
of patients and control subjects deserve further attention, since supporting evidence for association
between CDK5 gene and AD risk in the Dutch population exists.
Background
One of the neuropathological hallmarks in Alzheimer's
disease (AD) is the presence of neurofibrillary tangles,
which are composed of the microtubule-binding protein
tau that is hyperphosphorylated [1]. Cyclin-dependent
kinase 5 (CDK5) has been implicated as one of the major
protein kinases involved in the abnormal hyperphospho-
rylation of tau in AD [2], the activity of CDK5 has been
shown to be higher in the prefrontal cortex of AD brains
[3], and CDK5 has been described to be associated with
all stages of neurofibrillary pathology in AD brains [4]. In
addition, transgenic mice overexpressing CDK5 show a
dramatic increase in hyperphosphorylated, aggregated tau
[5]. CDK5 is an interesting genetic target for association
analysis of AD, and there are data available from 5 inde-
pendent samples [6-9]. To facilitate comparisons with the
Rotterdam Study that found a specific CDK5 haplotype
influencing the risk for AD in a Dutch population, we
examined the haplotype tagging SNPs identified by Arias-
Vásquez et al. [8] (rs2069442, rs2069454, rs891507,
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rs2069459, and rs9278) and one additional htSNP
(rs1549759), covering the complete genomic region of
CDK5, in a large series of Spanish AD cases and controls.
Methods
The study included 408 AD patients (66% women; mean
age at the time of study 76.8 years; SD 6.6; range 62–97
years; mean age at onset 73.5 years; SD 6.6; range 60–93
years) who met NINCDS/ADRDA criteria for probable AD
[10]. All AD cases were defined as sporadic because their
family history did not mention any first-degree relative
with dementia; this information was obtained by direct
interview of relatives. AD patients were consecutively
admitted to the Department of Neurology, University
Hospital "Marqués de Valdecilla", Santander, Spain, from
January 1997 to December 2001. The large majority of
patients were living in the community and had been
referred by their general practitioner; few had been admit-
ted from hospital wards or nursing home facilities. Con-
trol subjects were 444 unrelated individuals (68%
women; mean age 80.7 years; SD 7.6; range 62–100 years)
randomly selected from a nursing home. These subjects
had complete neurological and medical examinations
that showed that they were free of significant illness and
had Mini Mental State Examination scores of 28 or more,
which were verified by at least one subsequent annual fol-
low-up assessment. The controls arose from the same base
population as the cases. The AD and control samples were
Caucasians originating from a homogeneous population
in a limited geographical area in Northern Spain. All
patients and controls were ascertained to have parents and
grandparents born in Northern Spain to ensure ethnicity.
Consequently, possible confounding effects of the inclu-
sion in the study of members of different ethnic groups
have been minimized.
Blood samples were taken after written informed consent
had been obtained from the subjects or their representa-
tives. The study was approved by the ethical committee of
the University Hospital "Marqués de Valdecilla". Geno-
typing of CDK5 (rs9278, rs2069459, rs891507,
rs2069454, rs1549759, and rs2069442) polymorphism
was performed by a Taq-Man single-nucleotide-polymor-
phism assay (Applied Biosystems, Warrington, Cheshire,
UK) and an ABI PRISM 7000 sequence detection system
(Applied Biosystems). APOE genotyping was performed
by amplification of the 4th exon of the APOE gene by PCR
with biotinylated primers, followed by reverse hybridiza-
tion on nitrocellulose strips, using the INNO-LIPA ApoE
assay (Innogenetics NV, Ghent, Belgium).
Hardy-Weinberg equilibrium (HWE) was calculated for
the 6 htSNPs genotypes in the control population using
Pearson's χ2 statistics. We assessed pairwise linkage dise-
quilibrium (LD) between the 6 htSNPs by D' and r2 statis-
tics. Haplotype reconstruction and their frequencies in
cases and controls were estimated by an expectation-max-
imization algorithm. Pearson's χ2  statistics were per-
formed to compare allele distribution of the patients and
control for each htSNP. Haplotype frequencies were also
assessed using Pearson's χ2 using Haploview 3.32 software
http://www.broad.mit.edu/mpg/haploview. Rare haplo-
types (total frequency < 0.05) were excluded from the
analysis.
Results
In control groups, no deviations from Hardy-Weinberg
equilibrium were found for any of the 6 htSNPs (p values
ranging from 0.15 to 0.71). As shown in Table 1, the dis-
tribution of the allele and genotype frequencies of the
CDK5 htSNPs did not differ significantly between either
un-stratified or APOE-stratified AD and control groups.
Haplotype distributions were not significantly different
between cases and controls in the overall analysis or after
stratification by APOE ε4 allele (Table 2). There were no
major differences in allele, genotype or haplotype fre-
quencies of CDK5 polymorphisms in our total sample
associated to either age or gender subgroups (data not
shown).
Discussion
In a series of 85 early onset AD patients from Sweden and
104 early onset patients from the Netherlands, Rademak-
ers et al. [6] studied five tagging SNPs (rs2069442,
rs2069454, rs891507, rs2069459, and rs9278), observing
a two times increased AD risk in both patient samples for
carriers of the CDK5 rs2069454 C allele. Assessing the
association between these previously described htSNPs in
the CDK5 gene and late onset AD in a Dutch case-control
series, Arias-Vásquez et al. [8] observed a 1.8-fold (p =
0.001) increased risk of AD for carriers of the GG geno-
type of SNP rs2069442 in the CDK5 gene in non-carriers
of the APOE ε4 allele; in addition the CDK5 haplotype
(GGGGG) composed of 5'UTR (rs2069442), intron 5
(rs2069454), intron 9 (rs891507 and rs2069459) and
3'UTR (rs9278) was significantly associated with AD (OR
= 1.21, p = 0.05) in non-carriers of the APOE ε4 allele. We
genotyped the same variants in CDK5 as described by
Arias-Vásquez et al, but we were not able to confirm these
results, although we had enough power (80%) to detect
an OR as low as 1.43 for an increased risk effect of CDK5
haplotype in APOE ε4 allele non-carriers. Our failure to
replicate the main finding of Arias-Vásquez et al. could be
caused by many factors. We might have not been able to
detect the effect due to the fact that in the original study
the GGGGG haplotype conferred only a modest risk (OR
= 1.2), and the possibility of a type 2 error (false-negative)
must be taken into account. Another possibility is genetic
heterogeneity between our sample sets and those of the
original study. In two independent studies conducted inBMC Medical Genetics 2009, 10:68 http://www.biomedcentral.com/1471-2350/10/68
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Table 1: Distribution of CDK5 polymorphisms in patients and controls stratified by APOE ε4 allele
CDK5 polymorphism APOE ε4 allele noncarriers APOE ε4 allele carriers Total sample
Patients Controls Patients Controls Patients Controls
rs9278 GG 125 (0.67) 259 (0.71) 145 (0.66) 55 (0.71) 270 (0.66) 314 (0.71)
GA 61 (0.33) 96 (0.26) 69 (0.31) 22 (0.28) 130 (0.32) 118 (0.27)
AA 1 (0.00) 10 (0.03) 7 (0.03) 1 (0.01) 8 (0.02) 11 (0.02)
Total 187 365 221 78 408 443
Allele frequency G/A 0.83/0.17 0.84/0.16 0.81/0.19 0.85/0.15 0.82/0.18 0.84/0.16
rs2069459 GG 60 (0.34) 116 (0.32) 74 (0.35) 23 (0.29) 134 (0.34) 139 (0.31)
GT 83 (0.47) 169 (0.46) 100 (0.47) 39 (0.50) 183 (0.47) 208 (0.47)
TT 33 (0.19) 81 (0.22) 39 (0.18) 16 (0.21) 72 (0.19) 97 (0.22)
Total 176 366 213 78 389 444
Allele frequency G/T 0.58/0.42 0.55/0.45 0.58/0.42 0.54/0.46 0.58/0.42 0.55/0.45
rs891507 GG 101 (0.58) 211 (0.58) 123 (0.60) 48 (0.64) 224 (0.59) 259 (0.59)
GA 60 (0.35) 135 (0.37) 73 (0.36) 24 (0.32) 133 (0.35) 159 (0.36)
AA 12 (0.07) 16 (0.05) 9 (0.04) 3 (0.04) 21 (0.06) 19 (0.05)
Total 173 362 205 75 378 437
Allele frequency G/A 0.76/0.24 0.77/0.23 0.78/0.22 0.80/0.20 0.77/0.23 0.77/0.23
rs2069454 GG 171 (0.97) 320 (0.91) 199 (0.93) 68 (0.91) 370 (0.94) 388 (0.91)
GC 6 (0.03) 30 (0.09) 16 (0.07) 7 (0.09) 22 (0.06) 37 (0.09)
CC 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Total 177 350 215 75 392 425
Allele frequency G/C 0.98/0.02 0.96/0.04 0.96/0.04 0.95/0.05 0.97/0.03 0.96/0.04
rs1549759 GG 112 (0.69) 244 (0.70) 134 (0.67) 57 (0.74) 246 (0.68) 301 (0.70)
GA 48 (0.30) 100 (0.28) 59 (0.30) 20 (0.26) 107 (0.30) 120 (0.28)
AA 2 (0.01) 7 (0.02) 6 (0.03) 0 (0.00) 8 (0.02) 7 (0.02)
Total 162 351 199 77 361 428
Allele frequency G/A 0.84/0.16 0.84/0.16 0.82/0.18 0.87/0.13 0.83/0.17 0.84/0.16
rs2069442 CC 93 (0.55) 204 (0.60) 127 (0.63) 40 (0.57) 220 (0.60) 244 (0.59)
CG 65 (0.39) 121 (0.35) 60 (0.30) 25 (0.36) 125 (0.34) 146 (0.35)
GG 10 (0.06) 18 (0.05) 14 (0.07) 5 (0.07) 24 (0.06) 23 (0.06)
Total 168 343 201 70 369 413
Allele frequency C/G 0.75/0.25 0.76/0.24 0.78/0.22 0.75/0.25 0.77/0.23 0.77/0.23
Figures in parentheses indicate frequencies; p-values > 0.05 for all allelic and genotypic comparisons; p-values were not corrected for multiple 
comparisons.
Table 2: Haplotype association analysis between CDK5 gene and AD stratified by APOE ε4 allele
CDK5 haplotype APOE e4 allele noncarriers APOE e4 allele carriers Total sample
AD, control frequency p-value AD, control frequency p-value AD, control frequency p-value
GTGGGC 0.29, 0.31 0.30 0.29, 0.33 0.36 0.29, 0.31 0.30
GGGGGG 0.16, 0.17 0.59 0.14, 0.18 0.21 0.16, 0.17 0.59
GGGGAC 0.14, 0.12 0.16 0.15, 0.09 0.07 0.14, 0.12 0.16
AGGGGC 0.12, 0.11 0.57 0.14, 0.14 0.94 0.12, 0.11 0.57
GTAGGC 0.09, 0.10 0.74 0.07, 0.08 0.91 0.09, 0.10 0.74
GGAGGG 0.06, 0.05 0.53 0.06, 0.05 0.66 0.06, 0.05 0.53
Haplotype block consists of SNPs: rs9278, rs2069459, rs891507, rs2069454, rs1549759 and rs2069442. Rare haplotypes (total frequency < 0.05) 
were excluded from the analysis. P-values were not corrected for multiple comparisons.Publish with BioMed Central    and   every 
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USA and Netherlands [7], and Canada [9], respectively,
the CDK5 rs2069454 and rs891507 genetic variants were
not associated with AD. AlzGene database http://
www.alzgene.org reported meta-analyses of these two
CDK5 polymorphisms, both of which are studied here,
without any significant effects (based on nearly 10,000
cases and controls) [11].
Conclusion
Our negative findings in the Spanish population argue
against the hypothesis that CDK5 genetic variations are
causally related to AD risk. Still, additional studies using
different sets of patients and control subjects deserve fur-
ther attention, since supporting evidence for association
between CDK5 gene and AD risk in the Dutch population
exists.
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